Immatics (NASDAQ:IMTX) Director Perceptive Advisors Llc Buys 863,060 Shares

Immatics N.V. (NASDAQ:IMTX) Director Perceptive Advisors Llc bought 863,060 shares of the stock in a transaction dated Wednesday, August 26th. The shares were acquired at an average price of $8.69 per share, for a total transaction of $7,499,991.40. Following the completion of the transaction, the director owned 11,246,516 shares of the company’s stock, valued at approximately $97,732,224.04. The trade was a 8.31% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Immatics Trading Down 0.7%

Shares of Immatics stock traded down $0.07 during trading on Thursday, reaching $9.36. The company’s stock had a trading volume of 741,776 shares, compared to its average volume of 466,019. The company has a 50-day moving average price of $9.46 and a two-hundred day moving average price of $10.04. Immatics N.V. has a fifty-two week low of $5.05 and a fifty-two week high of $12.41. The firm has a market cap of $1.25 billion, a PE ratio of -5.03 and a beta of 1.33.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings results on Tuesday, August 18th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). Immatics had a negative return on equity of 47.41% and a negative net margin of 495.71%.The business had revenue of $10.44 million for the quarter, compared to analyst estimates of $12.42 million. On average, analysts predict that Immatics N.V. will post -2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on IMTX shares. Wall Street Zen downgraded shares of Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Chardan Capital restated a “buy” rating and issued a $25.00 price target on shares of Immatics in a research report on Tuesday, May 19th. Jefferies Financial Group set a $17.00 price target on Immatics in a research report on Tuesday. Finally, Weiss Ratings downgraded Immatics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.60.

Hedge Funds Weigh In On Immatics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC increased its stake in Immatics by 3.7% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 49,374 shares of the company’s stock valued at $518,000 after buying an additional 1,739 shares during the period. Bank of America Corp DE lifted its stake in shares of Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after acquiring an additional 2,231 shares during the period. Barclays PLC raised its holdings in Immatics by 11.4% during the fourth quarter. Barclays PLC now owns 28,185 shares of the company’s stock worth $296,000 after purchasing an additional 2,874 shares in the last quarter. Virtus Investment Advisers LLC raised its holdings in Immatics by 43.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 26,497 shares of the company’s stock worth $278,000 after purchasing an additional 7,965 shares in the last quarter. Finally, Quarry LP acquired a new stake in Immatics in the fourth quarter valued at about $84,000. 64.41% of the stock is currently owned by hedge funds and other institutional investors.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.